Show simple item record

dc.contributor.authorLi, Nianhu
dc.contributor.authorJiang, Yunpeng
dc.contributor.authorWooley, Paul H.
dc.contributor.authorXu, Zhanwang
dc.contributor.authorYang, Shang-You
dc.date.accessioned2013-07-08T20:33:23Z
dc.date.available2013-07-08T20:33:23Z
dc.date.issued2013-05
dc.identifier.citationLi, Nianhu; Jiang, Yunpeng; Wooley, Paul H.; Xu, Zhanwang; Yang, Shang-You. 2013. Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. Journal of Orthopaedic Science, v.18:no.3:pp 478-485en_US
dc.identifier.issn0949-2658
dc.identifier.issn1436-2023
dc.identifier.otherWOS:000319361700017
dc.identifier.urihttp://dx.doi.org/10.1007/s00776-013-0362-9
dc.identifier.urihttp://hdl.handle.net/10057/5887
dc.descriptionClick on the DOI link to access the article (may not be free).en_US
dc.description.abstractBACKGROUND: Osteoporosis is a common pathological condition that influences 20 % of women over 50 years of age. This condition decreases bone strength and increases the risk of bone fracture. Naringin is a major flavonoid found in grapefruit and an active compound extracted from a Chinese herbal medicine (Rhizoma Drynariae). Studies have shown that naringin possesses many pharmacological effects. The current study evaluated the influence of naringin on osteoblastic cell differentiation and proliferation, and assessed its therapeutic effects on a rat osteoporosis model. METHOD: The proliferation, differentiation, and function of rat bone marrow stromal cells (BMSCs) were determined following treatment with various concentrations of naringin. Ovariectomy (OVX)-induced osteoporotic rats were orally administered naringin daily at low, medium, and high dosages, while a control group received PBS for 2 months. Femoral X-ray images and microCT scans were used for bone mineral density (BMD) and BV/TV (bone volume/total volume) analyses, and histological assessments of left tibiae were employed to check for changes in trabecular thickness (Tb.Th) and trabecular space (Tb.Sp) in the groups. RESULTS: Naringin was effective at enhancing the proliferation and osteogenic differentiation of BMSCs, and a concentration of 10 μg/ml prompted the highest levels of osteocalcin expression among the in vitro study groups. There appeared to be a delayed response pattern of BMSCs to the naringin treatment. Naringin also effectively reversed OVX-induced bone loss via increasing BMD, bone volume, and trabecular thickness. The medium dose (300 mg/kg) appeared to be the optimal dosage for delivering satisfactory therapeutic effects. CONCLUSION: Naringin promotes the proliferation and differentiation of BMSCs, and increases osteocalcin expression. Naringin also effectively reverses ovariectomy-induced osteoporosis in rats. The study suggests that naringin administration may represent an effective treatment for osteoporosis.en_US
dc.description.sponsorshipShandong Provincial NaturalScience Foundation, China (No. Y2008C147), and research funding from Orthopaedic ResearchInstitute, Via Christi Wichita Hospitals Inc.en_US
dc.language.isoen_USen_US
dc.publisherSpringer Japanen_US
dc.relation.ispartofseriesJournal of Orthopaedic Science;v.18:no.3
dc.subjectBone-Formationen_US
dc.subjectMiceen_US
dc.subjectPlasticityen_US
dc.subjectCellsen_US
dc.subjectWomenen_US
dc.subjectModelen_US
dc.subjectAgeen_US
dc.subjectRheumatology
dc.subjectOrthopedics
dc.titleNaringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosisen_US
dc.typeArticleen_US
dc.description.versionPeer reviewed
dc.rights.holderCopyright © 2013, The Japanese Orthopaedic Association


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record